# CoVPN 3501: Eli Lilly (LY3819253) Protocol Funding

> **NIH NIH UM1** · FAMILY HEALTH INTERNATIONAL · 2021 · $8,980,894

## Abstract

Abstract:
The novel virus, SARS-CoV-2, which causes Coronavirus Disease – 2019 (COVID-19) is a significant threat to
public health. SARS-CoV-2 is both highly transmissible, as is evidenced by the current pandemic, and can
lead to clinically significant COVID-19 disease. In severe and critical cases SARS-CoV-2 infection causes
progressive pulmonary infection, complicated by respiratory failure, with a high prevalence of acute respiratory
distress syndrome. Out of all age groups, older adults have the greatest risk of experiencing severe COVID-19
disease and its associated complications (CDC 2020; Grabowski and Mor 2020).
Globally, there are a number of reports of COVID-19 rapidly spreading among the residents of skilled nursing
facilities. Sadly, these nursing home residents also have high associated rates of both morbidity and mortality
(Arons et al. 2020; Grabowski and Mor 2020; Graham et al. 2020). In the United States (US), at least 153,000
nursing home residents and employees have contracted COVID-19 disease and account for 35% of the
country’s deaths (Werner et al. 2020). With more than 1.3 million Americans living in nursing homes (CDC
2016), there is an urgent need for effective, preventative strategies.
CoVPN 3501 is a randomized, double-blind, placebo-controlled, prophylaxis study to evaluate the efficacy and
safety of the intravenous mAb, LY3819253, in preventing SARS-CoV-2 infection and COVID-19, compared to
placebo. It is expected that 1700-2400 participants (intent-to-treat [ITT] population) will be randomly assigned
to study intervention such that approximately 1300 SARS-CoV-2 negative participants are randomized in the
study with the goal of achieving approximately 33 events (in each of the primary and key secondary
endpoints).
This study will evaluate the effectiveness and safety of a monoclonal antibody (mAb), LY3819253, in
preventing SARS-CoV-2 infection and COVID-19 disease in nursing home facility staff and residents.

## Key facts

- **NIH application ID:** 10220271
- **Project number:** 3UM1AI068619-15S1
- **Recipient organization:** FAMILY HEALTH INTERNATIONAL
- **Principal Investigator:** MYRON Scott COHEN
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $8,980,894
- **Award type:** 3
- **Project period:** 2006-06-01 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10220271

## Citation

> US National Institutes of Health, RePORTER application 10220271, CoVPN 3501: Eli Lilly (LY3819253) Protocol Funding (3UM1AI068619-15S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10220271. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*